Latest News

Latest News

Clinical Trials Roundup | 19 June 2026

Clinical Trials Roundup | 19 June 2026

The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...

read more
Beyond the Injection: The Future of Holistic GLP-1 Care

Beyond the Injection: The Future of Holistic GLP-1 Care

The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more
Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Hyperfine Banks on $17.5 Million Public Stock Offering

Hyperfine Banks on $17.5 Million Public Stock Offering

Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...

read more
US Scientists Create Human Embryos from Skin Cells

US Scientists Create Human Embryos from Skin Cells

In a ground breaking advance in reproductive biology, researchers in the United States have for the first time created early-stage human embryos by converting DNA from skin cells into functional eggs and then fertilising them with sperm. Though still at an...

read more

Further News

Report Finds Seven in Ten Leaders Bullied by Their Teams

Healthcare organisations invest significantly in psychosocial risk frameworks, governance structures and leadership development. Yet a new international study highlights a type of organisational risk that most of those frameworks are not designed to detect. It is a...

How Traditional Japanese Wisdom can Bridge the Cardiovascular Health Gap

For decades, the global medical community has looked to Japan with a sense of wonder, specifically regarding the Japanese paradox of longevity. Epidemiological data consistently highlights a significant cardiovascular health gap between Japan and Western nations like...

Speech Could be a Key Marker in Neurodegenerative Disease Drug Trials

Speech is rapidly emerging as an important, non-invasive, digital clinical marker in neurodegenerative disease research, according to leading biotech SynaptixBio. The company has facilitated a study run by Australia-based speech analytics company Redenlab, in...

How AI-Driven Research is Reshaping Competitive Intelligence in Pharma

AI developments are happening at breakneck speed, with every sector and industry seeking new opportunities to seize and capitalise upon. AI-driven research is creating a fundamental shift for pharmaceutical competitive intelligence, moving away from a reactive, manual...

A ‘Bariatric-Level’ Obesity Drug Is Coming: Retatrutide and the UK Reality

The pharmaceutical press is having a very loud year. Eli Lilly's investigational triple-agonist retatrutide has produced the kind of phase 2 data that clinicians usually only see in editorials about the future, up to 24.2% mean body-weight reduction at 48 weeks in the...

Trump FDA Drug Approvals: Global Impact

Trump FDA Drug Approvals: How US Regulatory Upheaval Is Reshaping the Global Pharmaceutical Industry The United States Food and Drug Administration has long been regarded as the gold standard of drug regulation. When a medicine receives FDA approval, it carries a...

Most Supplement Companies Skip the RCT

Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...

Doctor, Patient, Agent: A New Clinical Triad for Medicine

By 6:45 AM, the dashboard is already waiting. A longevity physician sits down with coffee and reads what the monitoring agent assembled overnight: a falling seven-day HRV trend in a patient recovering from a viral illness, a queued statin titration for a...

Physiology: The Missing Layer in Precision Medicine

Precision medicine has been positioned as one of the most promising evolutions in modern healthcare. Gene panels. Liquid biopsies. Microbiome-targeted therapies. Multi-omics integration. The premise is compelling: the more precisely we can characterize biological...

Weekly News Roundup | 27 April 2026

Life science news 27 April 2026: Eli Lilly's $7 billion in vivo CAR-T deal, Trump's psychedelics executive order and a first-ever gene therapy for hearing loss headline a landmark week across global life science. Eli Lilly announced on 20 April its acquisition of...

Life Science Daily News: Join the Community

A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...

Clinical Trials Roundup | 24 April 2026

Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.